Equities

Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)55.82
  • Today's Change0.275 / 0.50%
  • Shares traded270.01k
  • 1 Year change+154.17%
  • Beta0.7486
Data delayed at least 15 minutes, as of Nov 22 2024 20:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform6
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Agios Pharmaceuticals Inc have a median target of 56.00, with a high estimate of 57.00 and a low estimate of 51.00. The median estimate represents a 0.83% increase from the last price of 55.54.
High2.6%57.00
Med0.8%56.00
Low-8.2%51.00

Earnings history & estimates in USD

On Oct 31, 2024, Agios Pharmaceuticals Inc reported 3rd quarter 2024 earnings of 16.22 per share. This result exceeded the 1.11 consensus of the 5 analysts covering the company and outperformed last year's 3rd quarter results by 17.86.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate-1.91%
Agios Pharmaceuticals Inc reported annual 2023 losses of -6.33 per share on Feb 15, 2024.
Average growth rate-9.37%
More ▼

Revenue history & estimates in USD

Agios Pharmaceuticals, Inc. had 3rd quarter 2024 revenues of 8.96m. This missed the 9.46m consensus estimate of the 10 analysts following the company. This was 59.81% above the prior year's 3rd quarter results.
Average growth rate+5.14%
Agios Pharmaceuticals, Inc. had revenues for the full year 2023 of 26.82m. This was 88.36% above the prior year's results.
Average growth rate+20.23%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.